Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and gdc 0941

lapatinib has been researched along with gdc 0941 in 6 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(gdc 0941)		Trials
(gdc 0941)		Recent Studies (post-2010) (gdc 0941)
1,9193051,44261056

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)gdc 0941 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformRattus norvegicus (Norway rat)0.052
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.0553
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alphaHomo sapiens (human)6.039
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)0.3219
High affinity nerve growth factor receptorHomo sapiens (human)2.85
Cytochrome P450 3A4Homo sapiens (human)0.0033
Cholesteryl ester transfer proteinHomo sapiens (human)0.032
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.0737
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)0.037
AcetylcholinesteraseRattus norvegicus (Norway rat)0.003
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.0415
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.1086
Serine/threonine-protein kinase mTORHomo sapiens (human)0.7449
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.1626
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)1.23
Phosphatidylinositol 3-kinase catalytic subunit type 3Homo sapiens (human)0.4534
Phosphoinositide 3-kinase regulatory subunit 5Homo sapiens (human)0.117
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)0.146

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Ajenjo, N; Albarrán, MI; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; Cuadrado-Urbano, M; García, AB; García-Serelde, B; Gómez de la Oliva, CA; Gómez-Casero, E; González Cantalapiedra, E; Hernández, AI; Klett, J; Martínez-González, S; Oyarzabal, J; Pastor, J; Rabal, O; Rodríguez-Arístegui, S; Varela, C1
Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM1

Reviews

1 review(s) available for lapatinib and gdc 0941

ArticleYear
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors

2021

Other Studies

5 other study(ies) available for lapatinib and gdc 0941

ArticleYear
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
    European journal of medicinal chemistry, 2019, Apr-15, Volume: 168

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinolines; Structure-Activity Relationship; Triazoles

2019